IGC Reports Financial Results for the December 31, 2021 Quarter

Rhea-AI Summary

India Globalization Capital reported Q3 results for the fiscal year 2022. The Company appointed James Moran to its Board of Directors, enhancing its expertise in healthcare. It completed a Phase 1 clinical trial for IGC-AD1, aimed at treating Alzheimer’s disease, showing promising results in reducing Neuropsychiatric Symptoms. The Life Sciences segment generated $134 thousand in revenue, while the Infrastructure segment brought in $8 thousand. The net loss was approximately $2.38 million, or ($0.05) per share. R&D expenses rose to $377 thousand, reflecting increased clinical trial activities.

Positive

• Appointment of James Moran to the Board of Directors enhances expertise.
• Promising results from Phase 1 trial of IGC-AD1 for Alzheimer's treatment.
• Life Sciences segment revenue increased to $134 thousand from $56 thousand year-over-year.

Negative

• Net loss of $2.38 million, slightly higher than the previous year's loss.
• Infrastructure segment revenue decreased to $8 thousand from $52 thousand year-over-year.
• Sustained uncertainty in revenue generation due to COVID-19 impacts.

POTOMAC, Md.--(BUSINESS WIRE)-- India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the three months ending December 31, 2021 – quarter three of the Company’s 2022 fiscal year.

Highlights include:

• The Company appointed former congressman James Moran to its Board of Directors. During his 24 years in Congress, Moran was recognized as a champion of innovative research and development in areas including healthcare and national security, environmental protection and sustainability, and international trade and fiscal responsibility.

• The Company completed a Phase 1 clinical trial for IGC-AD1, an investigational new Tetrahydrocannabinol (THC) based drug candidate designed to treat the symptoms of Alzheimer’s disease. As previously reported, the trial analyzed the safety and efficacy of different dosages, and the results were encouraging. Patients receiving the drug showed a decrease in agitation, anxiety, depression and other Neuropsychiatric Symptoms (NPS). From the trial, we gained valuable knowledge about the impact of dosing that will be studied further in additional clinical trials, subject to FDA approval. Complete findings have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA.

• While market conditions are subject to change, and there can be no assurances, the Company hopes and believes that, if IGC-AD1 can gain FDA approval, it can have a substantial impact on the lives of Alzheimer’s patients and their caregivers. We believe the demand for a drug that can reduce symptoms such as agitation, anxiety, and depression in Alzheimer’s patients is potentially significant. On September 17, 2021, the Company filed a patent application, IGC-513, to protect these initial trial findings.

• The Company is currently planning to proceed with additional clinical trials for IGC-AD1. We plan to submit a protocol to the FDA, for a large, double-blind, placebo-controlled Phase 2 trial to test the impact of IGC-AD1 in relieving agitation in dementia due to Alzheimer’s.

• On October 28, 2021, the Company won the Best CBD Topical award for its broad-spectrum hemp extract cream called Holi Wonder™ at the USA CBD Expo event held in Chicago, Illinois.

• On October 5, 2021, the Company received a Good Manufacturing Practice (GMP) certificate for its manufacturing and processing facility in Vancouver, Washington.

The Company’s financial results for the quarter ending December 31, 2021 relative to the same period a year ago:

• The Life Sciences segment, which includes the sale of hemp-based products such as lotion, gummies, and hand sanitizers was the largest revenue driver with $134 thousand in revenue for the quarter, compared to $56 thousand the year prior.

• The Infrastructure segment, which includes a construction contract, was $8 thousand in the quarter, relative to $52 thousand the year prior.

Primarily due to COVID-19, we expect volatility in both segments in the foreseeable future and it is difficult to predict when either segment will generate significant, stable revenue.

The following expense results refer to the quarters ending December 31, 2021, and December 31, 2020:

• Research and Development (R&D) expenses related to the Phase 1 clinical trial described above and product research in our Life Sciences segment was approximately $377 thousand compared to $154 thousand the year prior. We expect R&D expenses to increase with subsequent IGC-AD1 clinical trials, subject to FDA approval.

• Selling, General and Administrative (SG&A) expenses were $2.07 million in the quarter, a decrease of $116 thousand relative to $2.19 million the year prior. The SG&A decrease includes a one-time inventory-related adjustments of $245 thousand.

• Net loss was approximately $2.38 million or ($0.05) per share, compared to approximately $2.32 million or ($0.06) per share in the same quarter the prior year.

About IGC:

India Globalization Capital, Inc. (IGC), headquartered in Maryland, engages in the development of cannabinoid-based therapies for healthcare applications. IGC recently completed the first safety and tolerability clinical trial to treat symptoms of Alzheimer’s patients using a THC-based investigational new drug. The Company also operates an infrastructure business based in India. www.igcinc.us, www.igcpharma.com

Forward-Looking Statements:

This press release contains forward-looking statements that are based largely on IGC’s expectations and are subject to several risks and uncertainties, which may be beyond IGC’s control. Actual results could differ significantly from these if the Company is unable to commercialize one or more of the Company’s products or technologies, including the investigational new drug IGC-AD1 described in this press release. Other risks which could materially impact results include failure to obtain FDA approval for IGC-AD1 or additional clinical trials; unanticipated or unfavorable testing results from subsequent clinical trials; general economic conditions that are less favorable than expected; the impact of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, which are discussed in IGC’s SEC filings.

IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Reports on Form 10-K filed with the SEC on June 14, 2021, and Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2021, October 29, 2021, and February 10, 2022. Given these risks and uncertainties, we cannot assure the forward-looking information contained in this release will occur.

< Financial Tables to Follow>

India Globalization Capital, Inc.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
		December 31,			March 31,
		2021			2021
		($)			($)
ASSETS
Current assets:
Cash and cash equivalents		11,941			14,548
Accounts receivable, net		164			175
Inventory		5,428			5,478
Non-Marketable securities		-			80
Deposits and advances		1,704			3,236
Total current assets		19,237			23,517
Intangible assets, net		426			407
Property, plant and equipment, net		10,520			10,840
Non-Marketable securities		11			12
Claims and advances		612			603
Operating lease asset		482			488
Total long-term assets		12,051			12,350
Total assets		31,288			35,867
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		357			476
Accrued liabilities and others		919			1,588
Short-term loans		3			304
Total current liabilities		1,279			2,368
Long-term loans		145			276
Other liabilities		15			15
Operating lease liability		374			405
Total non-current liabilities		534			696
Total liabilities		1,813			3,064
Commitments and Contingencies – See Note 12
Stockholders' equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of December 31, 2021, and March 31, 2021.		-			-
Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 51,041,017 and 47,827,273 shares issued and outstanding as of December 31, 2021 and March 31, 2021, respectively.		114,894			109,720
Accumulated other comprehensive loss		(2,763	)		(2,774	)
Accumulated deficit		(82,656	)		(74,143	)
Total stockholders' equity		29,475			32,803
Total liabilities and stockholders' equity		31,288			35,867

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the
quarter ended December 31, 2021, filed with the SEC on February 10, 2022.

India Globalization Capital, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except loss per share and share data)
		Three months ended December 31,
		2021 ($)					2020 ($)
Revenue			142					108
Cost of revenue			(80	)				(94	)
Gross Profit			62					14
Selling, general and administrative expenses			(2,070	)				(2,186	)
Research and development expenses			(377	)				(154	)
Operating loss			(2,385	)				(2,326	)
Impairment of investment			-					-
Other income, net			4					3
Loss before income taxes			(2,381	)				(2,323	)
Net loss attributable to common stockholders			(2,381	)				(2,323	)
Foreign currency translation adjustments			77					40
Comprehensive loss			(2,304	)				(2,283	)
Loss per share attributable to common stockholders:
Basic & diluted		$	(0.05	)			$	(0.06	)
Weighted-average number of shares used in computing loss per share amounts:			51,053,191					41,304,365

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the
quarter ended December 31, 2021, filed with the SEC on February 10, 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005859/en/

Claudia Grimaldi

Phone: 301-983-0998

Source: India Globalization Capital, Inc.

FAQ

What were the financial results for IGC in Q3 of fiscal year 2022?

India Globalization Capital reported a net loss of approximately $2.38 million, with a revenue of $134 thousand from the Life Sciences segment.

What were the key highlights from IGC's Phase 1 clinical trial for IGC-AD1?

The Phase 1 clinical trial for IGC-AD1 showed promising results, with patients experiencing reduced agitation, anxiety, and depression.

How did IGC's revenue change compared to the previous year?

The Life Sciences segment revenue increased to $134 thousand from $56 thousand, while the Infrastructure segment revenue decreased to $8 thousand from $52 thousand.

What is the company's outlook regarding future clinical trials?

IGC plans to proceed with additional clinical trials for IGC-AD1, subject to FDA approval, aiming for a Phase 2 trial.